DDInter909 DDInter1233
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Imatinib {u} (Compound) causes {v} (Side Effect) Digestion impaired
Digestion impaired {u} (Side Effect) is caused by {v} (Compound) Mitotane
Imatinib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is downregulated by {v} (Compound) Mitotane
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpromazine
Chlorpromazine {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Mitotane
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Fentanyl
Fentanyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Fentanyl
Fentanyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Imatinib (Compound) causes Digestion impaired (Side Effect) and Digestion impaired (Side Effect) is caused by Mitotane (Compound)
Imatinib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Imatinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound) and Carbinoxamine (Compound) resembles Mitotane (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Chlorpheniramine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Mitotane (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is downregulated by Mitotane (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Mitotane (Compound)
Imatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Imatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Mitotane (Compound)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)